Literature DB >> 29572350

Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation.

Haijiao Zhang1, Cody Coblentz1, Kevin Watanabe-Smith2, Sophie Means1, Jasmine Means1, Julia E Maxson3, Jeffrey W Tyner4.   

Abstract

Granulocyte colony-stimulating factor (G-CSF or CSF3) and its receptor CSF3R regulate granulopoiesis, neutrophil function, and hematopoietic stem cell mobilization. Recent studies have uncovered an oncogenic role of mutations in the CSF3R gene in many hematologic malignancies. To find additional CSF3R mutations that give rise to cell transformation, we performed a cellular transformation assay in which murine interleukin 3 (IL-3)-dependent Ba/F3 cells were transduced with WT CSF3R plasmid and screened for spontaneous growth in the absence of IL-3. Any outgrowth clones were sequenced to identify CSF3R mutations with transformation capacity. We identified several novel mutations and determined that they transform cells via four distinct mechanisms: 1) cysteine- and disulfide bond-mediated dimerization (S581C); 2) polar, noncharged amino acid substitution at the transmembrane helix dimer interface at residue Thr-640; 3) increased internalization by a Glu-524 substitution that mimics a low G-CSF dose; and 4) hydrophobic amino acid substitutions in the membrane-proximal residues Thr-612, Thr-615, and Thr-618. Furthermore, the change in signaling activation was related to an altered CSF3R localization. We also found that CSF3R-induced STAT3 and ERK activations require CSF3R internalization, whereas STAT5 activation occurred at the cell surface. Cumulatively, we have expanded the regions of the CSF3R extracellular and transmembrane domains in which missense mutations exhibit leukemogenic capacity and have further elucidated the mechanistic underpinnings that underlie altered CSF3R expression, dimerization, and signaling activation.
© 2018 Zhang et al.

Entities:  

Keywords:  CSF3R; cell biology; cell signaling; cell surface receptor; endocytosis; mutagenesis; receptor expression; signal transduction; signaling transduction

Mesh:

Substances:

Year:  2018        PMID: 29572350      PMCID: PMC5950016          DOI: 10.1074/jbc.RA118.002417

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Signaling mechanisms coupled to tyrosines in the granulocyte colony-stimulating factor receptor orchestrate G-CSF-induced expansion of myeloid progenitor cells.

Authors:  Mirjam H A Hermans; Gert-Jan van de Geijn; Claudia Antonissen; Judith Gits; Daphne van Leeuwen; Alister C Ward; Ivo P Touw
Journal:  Blood       Date:  2002-12-05       Impact factor: 22.113

2.  Stimulation of Stat5 by granulocyte colony-stimulating factor (G-CSF) is modulated by two distinct cytoplasmic regions of the G-CSF receptor.

Authors:  F Dong; X Liu; J P de Koning; I P Touw; L Hennighausen; A Larner; P M Grimley
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

3.  A direct role for Met endocytosis in tumorigenesis.

Authors:  Carine Joffre; Rachel Barrow; Ludovic Ménard; Véronique Calleja; Ian R Hart; Stéphanie Kermorgant
Journal:  Nat Cell Biol       Date:  2011-06-05       Impact factor: 28.824

4.  The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.

Authors:  Julia E Maxson; Samuel B Luty; Jason D MacManiman; Jason C Paik; Jason Gotlib; Peter Greenberg; Swaleh Bahamadi; Samantha L Savage; Melissa L Abel; Christopher A Eide; Marc M Loriaux; Emily A Stevens; Jeffrey W Tyner
Journal:  Clin Cancer Res       Date:  2015-10-16       Impact factor: 12.531

5.  Endocytosis of activated TrkA: evidence that nerve growth factor induces formation of signaling endosomes.

Authors:  M L Grimes; J Zhou; E C Beattie; E C Yuen; D E Hall; J S Valletta; K S Topp; J H LaVail; N W Bunnett; W C Mobley
Journal:  J Neurosci       Date:  1996-12-15       Impact factor: 6.167

6.  Endosomal signaling of epidermal growth factor receptor stimulates signal transduction pathways leading to cell survival.

Authors:  Yi Wang; Steven Pennock; Xinmei Chen; Zhixiang Wang
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

7.  Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5.

Authors:  Fulu Liu; Ghada Kunter; Maxwell M Krem; William C Eades; Jennifer A Cain; Michael H Tomasson; Lothar Hennighausen; Daniel C Link
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

8.  Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.

Authors:  Masashi Sanada; Takahiro Suzuki; Lee-Yung Shih; Makoto Otsu; Motohiro Kato; Satoshi Yamazaki; Azusa Tamura; Hiroaki Honda; Mamiko Sakata-Yanagimoto; Keiki Kumano; Hideaki Oda; Tetsuya Yamagata; Junko Takita; Noriko Gotoh; Kumi Nakazaki; Norihiko Kawamata; Masafumi Onodera; Masaharu Nobuyoshi; Yasuhide Hayashi; Hiroshi Harada; Mineo Kurokawa; Shigeru Chiba; Hiraku Mori; Keiya Ozawa; Mitsuhiro Omine; Hisamaru Hirai; Hiromitsu Nakauchi; H Phillip Koeffler; Seishi Ogawa
Journal:  Nature       Date:  2009-07-20       Impact factor: 49.962

9.  Deletion of a critical internalization domain in the G-CSFR in acute myelogenous leukemia preceded by severe congenital neutropenia.

Authors:  M G Hunter; B R Avalos
Journal:  Blood       Date:  1999-01-15       Impact factor: 22.113

10.  Enhanced MAPK signaling is essential for CSF3R-induced leukemia.

Authors:  S Rohrabaugh; M Kesarwani; Z Kincaid; E Huber; J Leddonne; Z Siddiqui; Y Khalifa; K Komurov; H L Grimes; M Azam
Journal:  Leukemia       Date:  2016-12-27       Impact factor: 11.528

View more
  7 in total

1.  Epigenome-wide association study and network analysis for IgA Nephropathy from CD19+ B-cell in Chinese Population.

Authors:  Yifei Lin; Peiran Yin; Zhaozhong Zhu; Yuan Peng; Ming Li; Jun Li; Liming Liang; Xueqing Yu
Journal:  Epigenetics       Date:  2021-01-07       Impact factor: 4.528

2.  CSF3R truncation mutations in a patient with B-cell acute lymphoblastic leukemia and a favorable response to chemotherapy plus dasatinib.

Authors:  Marc S Schwartz; Matthew J Wieduwilt
Journal:  Leuk Res Rep       Date:  2020-06-08

3.  N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells.

Authors:  Yuuki Obata; Yasushi Hara; Isamu Shiina; Takatsugu Murata; Yasutaka Tasaki; Kyohei Suzuki; Keiichi Ito; Shou Tsugawa; Kouhei Yamawaki; Tsuyoshi Takahashi; Koji Okamoto; Toshirou Nishida; Ryo Abe
Journal:  Cell Commun Signal       Date:  2019-09-04       Impact factor: 5.712

4.  CSF3 Is a Potential Drug Target for the Treatment of COVID-19.

Authors:  Chao Fang; Jie Mei; Huixiang Tian; Yu-Ligh Liou; Dingchao Rong; Wei Zhang; Qianjin Liao; Nayiyuan Wu
Journal:  Front Physiol       Date:  2021-01-22       Impact factor: 4.566

5.  Colony-stimulating factor 3 receptor (CSF3R) M696T mutation does not impact on clinical outcomes of a Ph+ acute lymphoblastic leukemia patient.

Authors:  Xin Chen; Bichen Wang; Aiming Pang; Weiping Yuan; Erlie Jiang; Yajing Chu; Sizhou Feng; Mingzhe Han
Journal:  Blood Sci       Date:  2021-07-07

6.  Alzheimer's disease-associated inflammatory pathways might contribute to osteoporosis through the interaction between PROK2 and CSF3.

Authors:  Wenzheng Zhang; Ya Zhang; Naixia Hu; Anying Wang
Journal:  Front Neurol       Date:  2022-09-20       Impact factor: 4.086

7.  Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies.

Authors:  Amy M Trottier; Lawrence J Druhan; Ira L Kraft; Amanda Lance; Simone Feurstein; Maria Helgeson; Jeremy P Segal; Soma Das; Belinda R Avalos; Lucy A Godley
Journal:  Blood Adv       Date:  2020-10-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.